EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study

Jumpei Taniguchi iD, Shotaro Aso iD, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70162 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Jumpei Taniguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ceftriaxone, Anti-Bacterial Agents, Pneumonia, Cholangitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Health, Labor and Welfare, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftriaxone is believed to increase the risk of biliary infections due to pseudolithiasis caused by ceftriaxone‐calcium precipitation, but this risk is not well understood. This study aimed to investigate whether ceftriaxone use is associated with an increased risk of biliary infections in pneumonia patients using a national inpatient database.

Methods

We analyzed the Diagnosis Procedure Combination database in Japan, identifying pneumonia patients between July 2010 and March 2022. Patients were grouped by treatment: ceftriaxone versus ampicillin‐sulbactam or cefotaxime. Propensity score overlap‐weighting was used to adjust for confounding factors. The primary outcome was a composite measure, including cholecystitis or cholangitis during hospitalization, and any percutaneous, endoscopic, or surgical interventions on the biliary tract. Secondary outcomes included individual components of the primary outcome.

Results

Of the 1 503 885 eligible patients, 558 725 received ceftriaxone, while 945 160 were treated with either ampicillin‐sulbactam or cefotaxime. The mean dose of ceftriaxone was 1.7 g/day (standard deviation, 0.7 g/day), with a mean administration duration of 7.1 days (standard deviation, 3.8 days). Propensity score overlap‐weighting analysis revealed that ceftriaxone treatment was associated with an increased incidence of the composite outcome (0.22% vs. 0.18%; risk difference, 0.05%; 95% confidence interval, 0.03%–0.07%; p < 0.001), as well as the secondary outcomes, including cholecystitis or cholangitis during hospitalization and percutaneous or endoscopic drainage of the gallbladder or biliary tract.

Conclusion

Ceftriaxone use was associated with a slight increase in the risk of biliary infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftriaxoneAnti-Bacterial AgentsPneumoniaCholangitisCholecystitisHumansMaleFemaleRetrospective StudiesAgedMiddle AgedJapanPropensity ScoreAged, 80 and overDatabases, FactualAmpicillinSulbactamCefotaximeAdult

Stichwörter der Autor:innen

biliary infectionceftriaxonecholangitischolecystitispseudolithiasis

Substanzen

CeftriaxoneAnti-Bacterial AgentsAmpicillinSulbactamCefotaxime

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Jumpei Taniguchi, Shotaro Aso, Hideo Yasunaga

Förderung

  • The Ministry of Health, Labor and Welfare, Japan

Zitieren

APA

Taniguchi, J., Aso, S., Matsui, H., Fushimi, K., & Yasunaga, H. (2025). Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70162

Vancouver

Taniguchi J, Aso S, Matsui H, Fushimi K, Yasunaga H. Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70162

BibTeX
@article{Taniguchi2025,
  author = {Taniguchi, Jumpei and Aso, Shotaro and Matsui, Hiroki and Fushimi, Kiyohide and Yasunaga, Hideo},
  title = {Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70162}
}
Kostenlos starten →